Antibiotic Susceptibilities of Enterococci Isolated from Blood Cultures

Year 2015, Volume: 1 Issue: 4, 111 - 115, 01.10.2015

Süleyman Durmaz Türkan Toka Özer

https://doi.org/10.5455/umj.20150917042844

Abstract

Objective: The aim of this study was to determine the enterococci species and antimicrobial resistance rates of enteroccus strains isolated from blood cultures of inpatients. Materials and Methods: One hundred five Enterococcus spp. strains isolated from blood cultures sent from clinics at Osmaniye State Hospital Microbiology Laboratory between January 2011-December 2013 were included. The isolates were identified by conventional methods and Vitek 2 automated system. Antibiotic susceptibility tests were performed by disk-diffusion method and E-test. Statistical analysis was performed using chi-square test. Results: Enterococcus spp. strains evaluated, 54 51.4% were identified as E.faecalis and 51 48.6% as E.faecium. General Intensive Care Unit GICU is the section where most frequently isolated species of both enterococci. Other clinics were Dialysis unit, and Internal Medicine clinics. E.faecium strains were found to be resistant to ampicillin, erythromycin, ciprofloxacin. Resistance rates of E.faecalis strains against ampicillin, erythromycin, ciprofloxacin were 47%, 70.5%, 11.8%, respectively. High-level resistance to gentamicin and streptomycin were determined in 55.6%, 83.3% of E.faecium strains and in 23.5%, 11.8% of E.faecalis strains, respectively p≤0.05 . Two of E.faecium strains and 1 of E.faecalis from GICU were found to be resistant to teicoplanin and vancomycin. Linezolid was found most effective drug and resistance wasn’t determined in none of the strains. Conclusions: Three vancomycin and teicoplanin resistant strains isolated from blood cultures in our hospital show that the isolates mentioned above may cause significant problems in the future. In addition, linezolid may be a good alternative for the treatment of the resistant enterococcal infections in our hospital.

Keywords

Blood culture, Enterococcus facium, Enterococcus faecalis, antibiotic susceptibility, E-test, disk diffusion

References

• 1.Berktas M, Cıkman A, Parlak M, Guducuoğlu H, Ozkacmaz A. The Antibiotic resistance of Enterococcus strains isolated from blood cultures. Sakaryamj 2013;3:76-79.
• 2.Turk Dagı H, Arslan U, Tuncer EI. Antibiotic resistance in Enterococci isolated from blood cultures. Turkish Society Microb 2011;41:103-106.
• 3. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009; 155: 1749-1757.
• 4.Sava IG, Heikens E, Huebner J. Pathogenesis and immunity in enterococcal infections. Clin Microbiol Infect 2010;16:533-540.
• 5.De Fatima Silva Lopes M, Ribeiro T, Abrantes M, Figueiredo Marques JJ, Tenreiro R, Crespo MT. Antimicrobial resistance profiles of dairy and clinical isolates and type strains of enterococci. Int J Food Microbiol 2005;103:191-198.
• 6.Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. American journal of medicine 2006;119:970-976.
• 7.Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest Journal 2000;118:146-155.
• 8.Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine 2006;34:1589-1596
• 9.Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement M100-S18, CLSI, Wayne, Pa (2008).
• 10. Tunger O. The old and new treatment options for vancomycin-resistant enterococcal infections. Ankem Journal 2012;26:215-227.
• 11. Gozuboyuk G, Uyanik MH, Hancı H, Aktas O, Ozbek A. Antimicrobial susceptibility of Enterococcus strains isolated from blood cultures. Ankem Journal 2013;27:107-112.
• 12. Durmaz S, Kiraz A, Ozer TT, Percin D. Macrolidelincosamide-streptogramin B resistance phenotypes in Staphylococcus aureus. Eur J Gen Med 2014;11:217-220.
• 13. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.
• 14. Eksi F, Gayyurhan ED. Antibiotic susceptibility of Streptococcus and Enterococcus strains isolated from clinical specimens. Ankem Journal 2008;22:53-58.
• 15. Kalayci O, Yurtsever SG, Gungor S, Uzun B, Kurultay N. Evaluation of in vitro antibiotic sensitivity of Enterococci isolated from urine samples. Klimik Journal 2011;24:105-107.
• 16. Meric M, Ruzgar M, Gundes S, Willke A. Enterococcus species isolated from hospitalized patients and their antibiotic resistance patterns. Ankem Journal 2004;18:141-144.
• 17. Sumerkan B. Antibiotic resistance in Streptococcus pneumoniae and Enterococci: Map of Turkey (2003-2004). Ankem Journal 2005;19:61-65.
• 18. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in SENTRY Program (2005-2008). Braz J Infect Dis 2009;13:90-98.
• 19. Mert Dinc B, Aykut Arca E, Yağcı S, Karabiber N. In-vitro antibotic susceptibility of Enterococcus faecalis and Enterococcus faecium strains isolated from various clinical samples. Turk Hij Den Biyol Derg. 2009;66: 117-121.
• 20. Vural T, Sekercioglu AO, Ogunc D, Gultekin M, Colak D, Yesilipek A, et al. Vancomycin resistant Enterococcus faecium strain. ANKEM Journal 1999;13:1-4
• 21. Barrett JF. Linezolid Pharmacia Corp. Curr Opin Invest Drugs 2000;1:181-187.
• 22. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-1982
• 23. Jones RN, Ballow CH, Biedenbach DJ and ZAPS Study Group Medical Centers. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the “Zyvox Antimicrobial Potency Study” (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001; 40:59-66.